# Neuroelectrics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neuroelectrics

- Industry: Software
- Headquarters: Barcelona, Spain
- Website: www.neuroelectrics.com/
- Total disclosed funding: $18M
- Latest round: Series A (May 4, 2021)
- Investors on record: 1

## About

Neuroelectrics is a pioneering company focused on developing advanced neuromodulation solutions for brain disorders, leveraging innovative technology to deliver personalized healthcare treatments.Founded in 2012 in Barcelona, Spain, Neuroelectrics specializes in neuromodulation technologies, providing tools for brain disorder treatment. The company raised USD 17.5 mn in a SERIES A funding round on May 4, 2021, led by Morningside Venture Partners. The firm has established itself as a key player in the neurotherapeutics field under the leadership of CEO Ana Maiques.Neuroelectrics specializes in innovative solutions for brain disorders through its core product, the Starstim platform. This platform incorporates a headpiece designed for EEG monitoring and multi-channel neuromodulation using Transcranial Electrical Stimulation (tES). By employing a cloud-based approach, Neuroelectrics delivers personalized treatment protocols that are rooted in extensive neuroscience research and tailored to individual patient physiological data. The primary end-use cases addressed by these technologies include treating conditions such as depression and epilepsy, with a focus on restoring brain networks impaired by circuital dysfunction. The company's solutions are utilized by researchers and clinicians across various geographical markets, including Europe and North America, targeting both academic institutions and healthcare providers who seek to enhance patient outcomes through advanced brain stimulation therapies.Neuroelectrics generated revenue of USD 2,819,432.10 in 2020, with an EBITDA of USD 249,819.70. The company generates revenue through direct sales of its flagship products, including the Starstim platform and associated accessories, as well as through collaborations with research institutions and healthcare providers. The transaction structure predominantly involves B2B relationships where the company partners with hospitals and research entities to provide its neuromodulation technologies. Clients typically engage in subscription-based models or one-time purchases for the equipment, supported by ongoing service agreements for software updates and maintenance. The pricing for these proprietary products reflects the advanced technology and personalized treatment capabilities offered, positioning them as premium solutions within the market for brain health therapies. Neuroelectrics continues to expand its product offerings and service agreements to enhance its footprint in the growing sector of neurotherapeutics.Neuroelectrics aims to advance clinical trials for its platform targeting refractory focal epilepsy and at-home treatment of refractory depression. The recent funding of USD 17.5 mn will be utilized to accelerate these initiatives. The company is also focusing on expanding into new markets, particularly targeting further penetration in the North American healthcare sector by the end of 2022.

## Funding rounds

- Series A, May 4, 2021, $18M — Morningside

## Investors

- Morningside (https://capitalatlas.ai/funds/morningside) — Series A